| Literature DB >> 25006494 |
Abstract
Flavonoids and polyphenols are heterocyclic molecules that have been associated with beneficial effects on human health, such as reducing the risk of various diseases like cancer, diabetes, and cardiovascular and brain diseases. Protocatechuic acid (PCA) is a type of widely distributed naturally occurring phenolic acid. PCA has structural similarity with gallic acid, caffeic acid, vanillic acid, and syringic acid which are well-known antioxidant compounds. More than 500 plants contain PCA as active constituents imparting various pharmacological activity and these effects are due to their antioxidant activities, along with other possible mechanisms, such as anti-inflammatory properties and interaction with several enzymes. Over the past two decades, there have been an increasing number of publications on polyphenols and flavonoids, which demonstrate the importance of understanding the chemistry behind the antioxidant activities of both natural and synthesized compounds, considering the benefits from their dietary ingestion as well as pharmacological use. This work aims to review the pharmacological effects of PCA molecules in humans and the structural aspects that contribute to these effects.Entities:
Year: 2014 PMID: 25006494 PMCID: PMC4005030 DOI: 10.1155/2014/952943
Source DB: PubMed Journal: ISRN Pharmacol ISSN: 2090-5165
Figure 1Chemical Structure of protocatechuic acid.
Figure 2Pharmacological activity of protocatechuic acid.
Different biological sources and uses of protocatechuic acid.
| Sr. number | Biological source | Uses | Reference |
|---|---|---|---|
| 1 |
| Cancer chemopreventive | [ |
| 2 |
| Antifungal | [ |
| 3 |
| Antioxidant | [ |
| 4 |
| Antioxidant | [ |
| 5 |
| Antioxidant | [ |
| 6 |
| Antioxidant | [ |
| 7 |
| Antioxidant | [ |
| 8 |
| Antibacterial, | [ |
| 9 |
| Antioxidant | [ |
| 10 |
| Antioxidant | [ |
| 11 | Human metabolite of | Antioxidant | [ |
| 12 |
| Antispasmodic | [ |
| 13 |
| Antioxidant | [ |
| 14 |
| Antioxidant, anti-inflammatory, | [ |
| 15 |
| Antihypertensive, hepatoprotective, and anti-inflammatory | [ |
| 16 |
| Chemopreventive properties | [ |
| 17 |
| Bronchodilatatory, antispasmodic activity | [ |
| 18 |
| Antiviral, antiatherosclerotic, hyperlipidemic, and ischemic heart disease protective | [ |
| 19 | Fruit of | Anti-inflammatory, analgesic activity | [ |
| 20 |
| Antiageing | [ |
Evaluation of activities of protocatechuic acid in preventing different chemical carcinogenesis in rodents [30].
| Species/strain/gender of animals | Carcinogen/ | PCA dose/route | Target tissue | Response |
|---|---|---|---|---|
| F344 rats/males | 4-NQO | 500, 1000, and 2000 ppm/in diet | Oral cavity | Inhibition |
| F344 rats/males | 4-NQO | 2000 ppm/in diet | Oral cavity | Inhibition |
| Syrian golden | DMBA | 200 ppm/in diet | Buccal pouch/ | Inhibition |
| F344 rats/males | MNNG | 1500 ppm/in diet | Fore stomach/SCC | No effects |
| F344 rats/males | AOM | 1000, 2000 ppm/in diet | Colon/ADC | Inhibition |
| F344 rats/males | AOM | 250, 500, and 1000 ppm/in diet | Colon/ADC | Inhibition |
| Syrian golden | BOP | 500, 1000 ppm/in diet | Pancreas/ADC | Inhibition |
| F344 rats/males | DEN | 500, 1000 ppm/p.o. | Liver/AD | Inhibition |
| A/J mice/females | NNK | 1000 ppm/in diet | Lung/AD | No effects |
| F344 rats/males | BBN | 500, 1000, and 2000 ppm/in diet | Urinary | Inhibition |
| CD-1 mice/females | B[a]P/TPA | 5, 10, 20 mM | Skin/PAP | Inhibition |
| ICR mice/females | DMBA/TPA | 16, 160, and 1600 nM/topically to the skin 0; 40 min or 3 h before TPA | Skin/PAP | Inhibition (16 nM); |
| F344 rats/males | PhIP | 2000 ppm/in diet | Breast/ADC | No effects |
AD: adenoma; ADC: adenocarcinoma; AOM: azoxymethane; B[a]P: benzo[a]pyrene; BBN: N-butyl-N-(4-hydroxybutyl) nitrosamine; BOP: N-nitrosobis (2-oxopropyl) amine; DEN: N-diethylnitrosamine; DMBA: 7, 12-dimethyl-benz[a]anthracene; MMMG: N-methyl-N′-nitro-N-nitrosoguanidine; NNK: 4-(methyl-nitroso-amino)-1-(3-pyridyl)-1-butanone; 4-NQO: 4-nitroquinoline oxide; PAP: squamous cell papilloma; PhIP: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; SCC: squamous cell cancer; TCC: transitional cell carcinoma; TPA: 12-O-tetradecanoylphorbol 13-acetate.